Adult Dosing
Short-term treatment of insomnia
- 7.5-30 mg PO qhs; usual: 15 mg PO; in elderly/debilitated initial: 7.5 mg PO qhs
Pediatric Dosing
- Safety and effectiveness in pediatric patients has not been established
[Outline]
- Symptomatic treatment of insomnia should be initiated only after careful evaluation of patients, because sleep disturbances may be the presenting feature of a physical and/or psychiatric disorder. Failure of insomnia to remit after 7-10 days of therapy may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated
- Worsening of insomnia or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder
- Some of the important adverse events are dose related. Hence, use lowest effective dose in elderly
- Complex behaviors including sleep-driving, preparing and eating food, making phone calls, or having sex may occur with the use of the drug at therapeutic doses. Concomitant use of alcohol and other CNS depressants increases the risk of such behaviors; discontinue the drug in case of such events
- Angioedema involving the tongue, glottis or larynx and additional adverse events such as dyspnea, throat closing, or nausea and vomiting that suggest anaphylaxis, may occur after taking the first or subsequent doses of temazepam and could be fatal; do not re-challenge with the drug in patients who develop angioedema
- Patients should avoid engaging in hazardous activities requiring complete mental alertness, such as driving a motor vehicle or operating machinery during therapy, because of its CNS depressant effects
- Withdrawal signs and symptoms may occur following rapid reduction or abrupt discontinuation. If treatment is to be discontinued or the dose reduced, after prolonged therapy, gradually taper the dose
- Use lowest effective dose in elderly and/or debilitated patients
Cautions: Use cautiously in
Pregnancy Category:X
Breastfeeding: Temazepam is excreted in low levels in breastmilk and it has relatively short half-life, amounts ingested by the infant are small and would not be expected to cause any adverse effects in breastfed infants. Take dose after the infant's last feeding of the day (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 8 June 2011). Manufacturer advises caution when is administered to a nursing woman.
US Trade Name(s)
US Availability
temazepam (generic)
- CAPS: 7.5, 15, 22.5, 30 mg
Restoril
- CAPS: 7.5, 15, 22.5, 30 mg
Canadian Trade Name(s)
Canadian Availability
temazepam (generic)
Restoril
UK Trade Name(s)
UK Availability
temazepam (generic)
- CAPS: 10, 20 mg
- SOLN: 10 mg/5 mL
Australian Trade Name(s)
Australian Availability
temazepam (generic)
Normison, Temaze, Temtabs
[Outline]
Pricing data from www.DrugStore.com in U.S.A.
- Temazepam 30 MG CAPS [Bottle] (MYLAN)
30 mg = $14.99
90 mg = $25.97 - Temazepam 15 MG CAPS [Bottle] (MYLAN)
30 mg = $12.99
90 mg = $22.97 - Restoril 15 MG CAPS [Bottle] (MALLINCKRODT)
30 mg = $368.93
60 mg = $733.78 - Temazepam 7.5 MG CAPS [Bottle] (MALLINCKRODT PHARM)
30 mg = $155.99
90 mg = $449.97 - Restoril 22.5 MG CAPS [Bottle] (MALLINCKRODT)
30 mg = $348.75
90 mg = $1014.01 - Restoril 7.5 MG CAPS [Bottle] (MALLINCKRODT)
30 mg = $348.76
60 mg = $584.6 - Restoril 30 MG CAPS [Bottle] (MALLINCKRODT)
30 mg = $348.76
60 mg = $685.44 - Temazepam 22.5 MG CAPS [Bottle] (MALLINCKRODT PHARM)
30 mg = $199.98
90 mg = $579.99
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.